Abstracts tagged "outcomes and systemic lupus erythematosus (SLE)"

Abstract Number: 1670 • 2018 ACR/ARHP Annual Meeting
Disease Course Patterns in Systemic Lupus Erythematosus: Impact on Long-Term Outcomes
Konstantinos Tselios, Dafna D Gladman, Zahi Touma, Jiandong Su, Nicole Anderson and Murray Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Previous studies have described three patterns of disease activity over time in systemic lupus erythematosus (SLE), namely long quiescence, relapsing remitting, and persistently active.…
Abstract Number: 2667 • 2018 ACR/ARHP Annual Meeting
Sledai and Mex-Sledai Glucocorticoid Indices As Predictors of Damage and Mortality in Multinational Multiethnic Latin American Cohort
Manuel Ugarte-Gil^1,2, Ines Segami^3,4, Guillermina Harvey⁵, Guillermo J. Pons-Estel⁶, Rosana Quintana⁷, Cristina Reategui-Sokolova⁸, Jorge Cieza⁴, Luis J. Catoggio⁹, Mercedes Garcia¹⁰, Verónica Saurit¹¹, Francisco Caeiro¹², Cristina Drenkard¹³, Guillermo Berbotto¹⁴, Emilia Sato¹⁵, Lilian Costallat¹⁶, Eloisa Bonfa¹⁷, Joao C. Tavares Brenol¹⁸, Nilzio A Da Silva¹⁹, Fernando Cavalcanti²⁰, Antonio Iglesias-Gamarra²¹, Marlene Guibert-Toledano²², Gil A. Reyes²², Loreto Massardo²³, Oscar J Neira²⁴, Mario H Cardiel²⁵, Leonor Barile²⁶, Mary Carmen Amigo²⁷, Luis H. Silveira²⁸, Ignacio Garcia de la Torre²⁹, Eduardo Acevedo-Vasquez², Rosa Chacón-Díaz³⁰, Maria H Esteva Spinetti³¹, Graciela S. Alarcón^32,33 and Bernardo A Pons-Estel⁷, ¹Rheumatology, Universidad Científica del Sur, Lima, Peru, ²Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ³Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁴Hospital Edgardo Rebagliati Martins. EsSalud, Lima, Peru, ⁵Escuela de Estadística, Universidad Nacional de Rosario, Rosario, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario. Argentina, Rosario, Argentina, ⁷Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Rosario, Argentina, ⁸Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁹Rheumatology Unit, Internal Medicine Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁰Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, ¹¹Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ¹²Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ¹³Medicine/Rheumatology, Emory University, Atlanta, GA, ¹⁴Hospital Escuela Eva Perón, Granadero Baigorria, Argentina, Granadero Baigorria, Argentina, ¹⁵Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ¹⁶Universidade Estadual da Campinas, Campinas, Brazil, ¹⁷Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ¹⁸Hospital da Clinicas da Porto Alegre, Porto Alegre, Brazil, ¹⁹Faculdade de Medicina da Universidade Federal de Goiás, Goiania, Brazil, ²⁰Universidade Federal da Pernambuco, Pernambuco, Brazil, ²¹Universidad Nacional de Colombia, Bogota, Colombia, ²²Centro de Investigaciones Médico-Quirúrgicas (CIMEQ), Havana, Cuba, ²³Centro de Biología Celular y Biomedicina (CEBICEM), Universidad San Sebastián, Santiago, Chile, ²⁴Hospital del Salvador, Facultad de Medicina, Universidad de Chile, Santiago, Chile, ²⁵Centro de Investigación Clínica de Morelia, Morelia, Mexico, ²⁶Hospital Ángeles del Pedregal, Mexico, Mexico, ²⁷Rheumatology, Centro Medico ABC, Mexico, Mexico, ²⁸Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, ²⁹Hospital General de Occidente, Guadalajara, Mexico, ³⁰Servicio de Reumatología, Hospital Universitario de Caracas, Centro Nacional de Enfermedades Reumáticas, Caracas, Venezuela, ³¹Hospital Central de San Cristóbal, San Cristobal, Venezuela (Bolivarian Republic of), ³²Universidad Peruana Cayetano Heredia, Lima, Peru, ³³Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Disease activity is one of the major predictors of damage accrual and mortality in systemic lupus erythematosus (SLE). Glucocorticoid use, especially in high dose,…
Abstract Number: 715 • 2017 ACR/ARHP Annual Meeting
Long-Term Outcome of Demyelnating Syndrome in Systemic Lupus Erythematosus: A Longitudinal Study
Jamal A. Mikdashi¹ and Ipolia Ramadan², ¹Div of Rheumatology, Univ of Maryland Schl of Med, Baltimore, MD, ²National Institue of Health, Rockville, MD
Background/Purpose: Demyelinating syndromes (DS) in systemic lupus erythematosus (SLE) are characterized by inflammation, demyelination and neurodegeneration. Little is known, however, about the tenet of dissemination…
Abstract Number: 1839 • 2017 ACR/ARHP Annual Meeting
Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials
Michal Abrahamowicz¹, John M. Esdaile², Rosalind Ramsey-Goldman³, Lee S. Simon⁴, Vibeke Strand⁵ and Peter E. Lipsky⁶, ¹Departmernt of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³FSM, Northwestern University, Chicago, IL, ⁴SDG LLC Consulting, West Newton, MA, ⁵Stanford University, Palo Alto, CA, ⁶AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Randomized controlled trials (RCTs) of new SLE treatments are hampered by the lack of effective outcome measures that are responsive to change and clinically…
Abstract Number: 2623 • 2017 ACR/ARHP Annual Meeting
Association between Smoking Status and the Clinical and Serological Characteristics at the Onset of Systemic Lupus Erythematosus. an Inception Cohort Analysis
Jorge Sanchez-Guerrero¹, Afra Al Dhaheri², Stacey Morrison³, Jiandong Su⁴, Dafna D Gladman⁵ and Murray Urowitz⁶, ¹Division of Rheumatology, Toronto Western Hospital, Toronto, AB, Canada, ²Tawam Hospital, Al Ain, United Arab Emirates, ³Rheumatology, Krembil Research Institute, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Cigarette smoking regulates both innate and adaptive immunity and is associated with numerous diseases. In some inflammatory diseases smoking is associated with deleterious effects…
Abstract Number: 745 • 2016 ACR/ARHP Annual Meeting
Clinical and Laboratory Correlates of Response in a Phase 3 Clinical Trial of Belimumab or Placebo Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)
Ronald F. van Vollenhoven¹, William Stohl², Richard Furie³, Norma Lynn Fox⁴, James Groark⁵, Damon Bass⁵, Milena Kurtinecz⁵, Bonnie Pobiner⁶, William Eastman⁶, Tania Gonzalez-Rivera⁵ and David Gordon⁵, ¹Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴GSK, Potomac, MD, ⁵GSK, Philadelphia, PA, ⁶GSK, Research Triangle Park, NC
Background/Purpose: The SRI (SLE responder index) is a composite measure established as a primary endpoint in SLE clinical trials. However, it has been questioned whether…
Abstract Number: 1777 • 2016 ACR/ARHP Annual Meeting
The Accumulation of Organ Damage, Public Insurance Enrollment and Youth Are Associated with Increased Hospitalizations in a Population-Based Cohort of Lupus Patient
S. Sam Lim¹, Gaobin Bao¹, Hong J. Kan², Bonnie Pobiner³, Julie Priest⁴, William Eastman³, Kirk Easley⁵ and Cristina Drenkard⁶, ¹Medicine, Emory University School of Medicine, Atlanta, GA, ²John Hopkins University, Baltimore, MD, ³GSK, Research Triangle Park, NC, ⁴WW Epidemiology, GlaxoSmithKline, Durham, NC, ⁵Biostatistics, Emory University, Atlanta, GA, ⁶Emory University School of Medicine, Atlanta, GA
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) are frequently hospitalized. Determining factors associated with hospitalization rates may help to identify patients at highest risk for…
Abstract Number: 1968 • 2016 ACR/ARHP Annual Meeting
Adverse Childhood Experiences and Outcomes of Systemic Lupus Erythematosus
Laura Trupin¹, Patricia P. Katz¹, Cristina Lanata¹, Edward H. Yelin¹, Lindsey A. Criswell¹, Charles G. Helmick², Jinoos Yazdany¹ and Maria Dall'Era¹, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Adverse childhood experiences such as extreme deprivation, neglect, abuse, parental separation or incarceration, have been associated with adult health status, including onset of rheumatic…
Abstract Number: 2839 • 2016 ACR/ARHP Annual Meeting
Circulating CD4+CD28null T-Cells Predict the Occurrence of New Lung Damage in Systemic Lupus Erythematosus (SLE) Patients
Manuel Ugarte-Gil^1,2, César Sánchez-Zúñiga³, Rocio V. Gamboa-Cardenas¹, Madeley Aliaga-Zamudio⁴, Francisco Zevallos¹, Ana Mosqueira-Riveros⁴, Mariela Medina¹, Giannina Tineo-Pozo⁴, Claudia Elera-Fitzcarrald¹, Victor Pimentel-Quiroz¹, Omar Sarmiento-Velasquez¹, Jorge M. Cucho-Venegas¹, Jose Alfaro-Lozano¹, Zoila Rodriguez-Bellido^1,5, Cesar A. Pastor-Asurza^1,5, Graciela S. Alarcón⁶ and Risto Perich-Campos^1,5, ¹Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ²Universidad Cientifica del Sur, Lima, Peru, ³Diagnostic Support, Hospital Grau. EsSalud, Lima, Peru, ⁴Molecular Biology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁵Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Peripheral CD4+CD28null T-cells constitute a subset of long-lived cytotoxic CD4+ T-cell with pro-inflammatory functions. This T-cell subpopulation has been reported to be associated with…
Abstract Number: 2842 • 2016 ACR/ARHP Annual Meeting
Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis
William Fung¹, Jiandong Su² and Zahi Touma³, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) manifests with proteinuria and/or active urine sediment. Renal composite indices include proteinuria, urinary active sediment (RBCs, casts) and serum creatinine.…
Abstract Number: 54 • 2015 ACR/ARHP Annual Meeting
Impact of Age at Disease Diagnosis on Clinical Manifestations, Disease Activity, and Outcomes in Patients with Systemic Lupus Erythematosus: Single-Center Prospective Cohort Study
Il Woong Sohn¹, Young Bin Joo¹, Soyoung Won², Seung Taek Song¹, Seung Lee³, Hye-Jin Jeong³ and Sang-Cheol Bae¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that affects frequently in their 20s and 30s. However, SLE could develop in other age group…
Abstract Number: 404 • 2015 ACR/ARHP Annual Meeting
Long-Term Outcomes of Macrophage Activation Syndrome in Childhood-Onset Systemic Lupus Erythematosus
Roberto Ezequiel Borgia¹, Maya Gerstein¹, Deborah M. Levy², Earl Silverman² and Linda T Hiraki², ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening inflammatory complication of childhood-onset systemic lupus erythematosus (cSLE). There are few reports of long-term outcomes of MAS complicating cSLE.…
Abstract Number: 778 • 2015 ACR/ARHP Annual Meeting
Associations Between Autoantibodies and Clinical Manifestations in Systemic Lupus Erythematosus: Data from a Multiethnic Latin American Cohort
Manuel Ugarte-Gil^1,2, Daniel Wojdyla³, Ignacio Garcia-Valladares⁴, Rocio V. Gamboa-Cardenas¹, Yelitza Gonzalez-Bello^5,6, Guillermo J. Pons-Estel⁷, Cesar A. Pastor-Asurza^1,8, Ignacio Garcia-De La Torre^9,10, Graciela S. Alarcon¹¹, Bernado Pons-Estel¹² and GLADEL (Grupo Latinoamericano de Estudio de Lupus), ¹Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ²Universidad Cientifica del Sur, Lima, Peru, ³Universidad Nacional de Rosario, Argentina, Rosario, Argentina, ⁴Centro de Estudios de Investigación Básica y Clínica, SC., Guadalajara, Jalisco, Mexico, ⁵Immunology and Rheumatology, Hospital General de Occidente, Secretaria de Salud Jalisco, Guadalajara, Jalisco, Mexico, ⁶Immunology and Rheumatlogy, Universidad de Guadalajara, Zapopan, Jalisco, Mexico, ⁷Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, ⁸Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁹Immunology and Rheumatology, Hospital General de Occidente, Secretaria de Salud Jalisco, Zapopan, Jalisco, Mexico, ¹⁰Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, ¹¹Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹²Hospital Provincial de Rosario, Rosario, Argentina
Background/Purpose: Analyses of the association between autoantibodies and SLE clinical manifestations using cluster analyses assume that centroid and within-cluster residuals are similar inside the cluster…
Abstract Number: 2651 • 2014 ACR/ARHP Annual Meeting
Predictors of Therapeutic Outcomes in Patients with Neuropsychiatric Systemic Lupus Erythematosus
Kunihiro Ichinose¹, Kazuhiko Arima², Masataka Umeda¹, Shoichi Fukui³, Ayako Nishino¹, Yoshikazu Nakashima¹, Takahisa Suzuki¹, Yoshiro Horai⁴, Tomohiro Koga⁴, Shin-ya Kawashiri², Naoki Iwamoto¹, Mami Tamai¹, Hideki Nakamura¹, Tomoki Origuchi⁵ and Atsushi Kawakami¹, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Nagasaki, Japan, ⁴Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious organ disorder with a variety of symptoms. Despite advances in the understanding of the immunopathogenic and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].